NEW YORK, August 9, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Jazz Pharmaceuticals plc (NASDAQ: JAZZ), ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Santarus, Inc. (NASDAQ: SNTS), and Incyte Corporation (NASDAQ: INCY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Jazz Pharmaceuticals plc Research Report
On August 6, 2013, Jazz Pharmaceuticals plc (Jazz) released its Q2 2013 financial results with reported revenues of $208.2 million versus $124.2 million in Q2 2012. According to the Company, revenue growth was attributable to increased net sales of Xyrem and the inclusion of Erwinaze product sales for the full reporting period. Adjusted net income stood at $88.3 million or $1.43 per diluted share, compared to $66.2 million or $1.09 per diluted share in Q2 2012. Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals plc, commented, "We remain committed to creating long-term shareholder value through disciplined investments to support expansion in our research and development, commercial and operational capacities and pursuit of promising corporate development opportunities." The Company expects its revenues for full-year 2013 to be in the range of $860 million to $880 million. The Full Research Report on Jazz Pharmaceuticals plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5fe3_JAZZ]
ACADIA Pharmaceuticals, Inc. Research Report
On August 6, 2013, Acadia Pharmaceuticals Inc. (Acadia) reported its Q2 2013 financial results with total revenues of $451,000 compared to $599,000 in Q2 2012. The Company reported a net loss of $9.1 million or $0.11 per common share compared to a net loss of $5.4 million or $0.10 per common share in Q2 2012. Uli Hacksell, Ph.D., ACADIA's CEO, said, "The second quarter of 2013 was a game-changing period for ACADIA, highlighted by establishing an expedited path to an NDA filing for pimavanserin and by strengthening our balance sheet through our public offering, we plan to build on the positive momentum of the first half of 2013 by continuing to advance our pipeline, led by pimavanserin, which we believe positions ACADIA with multiple attractive product and commercial opportunities." The Full Research Report on ACADIA Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/3eb7_ACAD]
Arena Pharmaceuticals, Inc. Research Report
On August 1, 2013, Arena Pharmaceuticals Inc. (Arena) reported its Q2 2013 financial results with reported revenues totaling $68.9 million compared to $22 million in Q2 2012. Net income attributable to common stockholders stood at $40.1 million or $0.18 per share compared to net loss of $22.1 million or $0.12 per share in Q2 2012. During the quarter, the Company achieved a total of $1.3 million in net products sales, which is 31.5% of Eisai's net product sales of BELVIQ. Jack Lief, Arena's President and CEO, said, "We are very encouraged by the positive response from patients and physicians since BELVIQ became available in US pharmacies on June 11, while it is still early in the launch, the progress made to date reinforces the significant opportunity we see for BELVIQ in the medical management of overweight and obese patients." The Full Research Report on Arena Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/6a95_ARNA]
Santarus, Inc. Research Report
On August 6, 2013, Santarus, Inc. (Santarus) reported its Q2 2013 financial results with total revenues of $89.4 million, an 89.4% YoY growth. Non-GAAP adjusted earnings totaled $24.3 million or $0.31 per diluted share, compared to $7.1 million or $0.10 in Q2 2012. Net income for the quarter totaled $73.5 million or $0.94 per diluted share compared to $3.4 million or $0.05 per diluted share in Q2 2012. Gerald T. Proehl, President and CEO of Santarus, said, "Our commercial efforts continue to drive strong financial performance with encouraging market uptake for UCERIS and significant contributions from GLUMETZA and ZEGERID." The Company raised its financial outlook for full-year 2013 and now expects revenue to be in the range of $355 million to $360 million, non-GAAP adjusted earnings within $97 million to $101 million range, and diluted non-GAAP adjusted EPS to be in the range of $1.21 to $1.26. The Full Research Report on Santarus, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/22f8_SNTS]
Incyte Corporation Research Report
On August 1, 2013, Incyte Corp. (Incyte) reported its Q2 2013 financial results with total revenues of $101.7 million compared to $86.5 million in Q2 2012. Net loss for the quarter was $2.6 million or $0.02 per share against net income of $4 million or $0.03 per share in Q2 2012. Net product revenues from Jakafi, a treatment of intermediate or high-risk myelofibrosis, totaled $54.1 million compared to $29.7 million in Q2 2012, while contract revenue declined 26.4% YoY to $41.7 million. Paul A. Friedman, M.D., Incyte's President and CEO, stated, "The underlying demand for Jakafi was strong in the second quarter, leading to our decision to increase guidance for 2013." The Company now anticipates full-year 2013 net product revenues from Jakafi to be in the range of $220 million to $230 million. The Full Research Report on Incyte Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/076e_INCY]
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
|SOURCE Analysts' Corner|
Copyright©2012 PR Newswire.
All rights reserved